In support of this view, targeting IL-23 pathway, IL-17 production or action by using IL-17R antagonist and IL-17A-blocking antibodies have been shown to attenuate autoimmune diseases (Hueber et al., 2010; Yeilding et al., 2011; Leonardi et al., 2012; Papp et al., 2012; Sofen et al., 2014). This evidence concerns the gene IL37 and autoimmune disease.